The goal of this clinical trial is to compare the antiplatelet efficacy of aspirin combined with clopidogrel and aspirin combined with half-dose ticagrelor in in patients with unruptured intracranial aneurysms with normal CYP2C19 metabolizer phenotype. The main questions it aims to answer are:
If aspirin combined with half-dose ticagrelor is comparable to or better than aspirin combined with clopidogrel? What medical problems do participants have when taking aspirin combined with half-dose ticagrelor? Researchers will compare aspirin combined with half-dose ticagrelor to aspirin combined with clopidogrel to see if aspirin combined with half-dose ticagrelor works to treat patients with unruptured intracranial aneurysms received endovascular treatment.
Participants will:
Take aspirin combined with half-dose ticagrelor or aspirin combined with clopidogrel every day for 6 months Visit the clinic 1 month and 6 months for checkups and tests
Patients with unruptured intracranial aneurysms who are scheduled for stent-assisted embolization;
mRS score less than or equal to 2 on admission;
Normal CYP2C19 metabolizer genotype;
Age 20 or above, 70 or below, regardless of gender;
Use of drugs that affect coagulation function or significant abnormalities in platelet/coagulation function before admission;
Previous history of cardiovascular and cerebrovascular disease;
Complications of major organ dysfunction, chronic inflammatory diseases or malignant tumors at admission;
Known allergy or contraindication to heparin, aspirin, clopidogrel, or ticagrelor;